- 65% of patients achieved an ISGA score of 0 (“clear”) or 1 (“almost clear”) after four weeks of treatment.
- 47% of patients achieved an ISGA score of 0 (“clear”) or 1 (“almost clear”) with a minimum 2-grade improvement after four weeks of treatment.
- Mean pruritus (itching) scores improved by 62% after four weeks of treatment.
- Patients demonstrated an average 78% reduction in affected body surface area.
- AN2728 was generally safe and well-tolerated with the most common AE’s being application site reactions.
- Overall blood levels in pediatrics and adolescents were low and were similar to those previously observed in adults after adjusting for percent BSA treated.
- We are currently conducting a Thorough QTc (TQT) study (required by the FDA for all new chemical entities) in healthy adults to investigate the risk of adverse ECG effects. We expect results from this study before the end of 2013.
- Subject to the results of the TQT study and an End of Phase 2 meeting with the FDA in the first quarter of 2014, we plan to initiate a Phase 3 study in atopic dermatitis in the first half of 2014.
Conference Call and WebcastAnacor will host a conference call today at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results of this study. The call can be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and can be accessed on the Events and Presentations page, under Investors, on the company’s website at www.anacor.com and will be available for three months following the call. About Anacor Pharmaceuticals Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. Anacor has also discovered three other compounds that have been out-licensed for further development — one is licensed to Eli Lilly and Company for the treatment of an animal health indication, the second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness) and the third compound is licensed to GlaxoSmithKline, LLC for development in tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit http://www.anacor.com. Forward-Looking Statements This release contains forward-looking statements, including statements regarding our milestones and clinical plans. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including the timing of data and results from our TQT study, the timing and outcome of an End of Phase 2 meeting with the FDA, the timing of the initiation of a Phase 3 study for AN2728; the potential for success of AN2728, and other matters that are described in Anacor’s Annual Report on Form 10-K for the year ended December 31, 2012, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.